home > ict > spring 2021 > the biotech journey: from lab development to clinical delivery
International Clinical Trials

The Biotech Journey: From Lab Development to Clinical Delivery

Biotechnology and emerging biopharmaceutical companies face countless challenges as they look to advance their drug to market. From the increasing clinical trial costs through each phase of development, to the fierce asset and patient competition ubiquitous within each stage, it can often feel like a mad dash to the finish line. Furthermore, with the COVID-19 pandemic jump-starting rapid global modernisation of clinical trials, coupled with increased investment in the biopharma sector, there is mounting pressure to have technological solutions in place to recruit and retain patients and drive innovation, efficiency, and speed.

To increase the probability of efficient and effective global trials, as well as to bring value to each phase of drug development towards commercialisation, many biotech companies engage CROs for support. Considerations for selecting a partner that can de-risk the challenges of bringing a drug to market are paramount for the biopharma sector.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Erin Finot, MBA, is Vice President of Immuno- Oncology at IQVIA Biotech. She is responsible for leading the teamís strategic direction to help sponsors focused on immuno-oncology trial programmes meet their goals. As advancements in immuno-oncology continue to transform cancer care, Erin guides sponsors through a dynamic landscape with more than 20 years of experience in global clinical research and drug development processes, including adoptive cellular trials. Erin has a Bachelorís in Biology from the University of California, Berkeley, US, and a Masterís degree in Immunology from the University of Virginia, US, providing a solid foundation for her therapeutic expertise.
Print this page
Send to a friend
Privacy statement
News and Press Releases

LifeArc Joins Forces with Cystic Fibrosis Trust and Medicines Discovery Catapult to Strengthen Antimicrobial Discovery Efforts

LifeArc, a national medical research charity, is joining the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate in a strategic partnership alongside Cystic Fibrosis Trust and Medicines Discovery Catapult (MDC).
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement